MarketInOut Stock Screener Log In | Sign Up
 

Halozyme Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 08/24/2026 16:00
Halozyme Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization12,044 mln
Float112 mln
Earnings Date11/09/2026

EPS

3.41
Stretched

P / E

31.86
Overvalued

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-1.9
Caution advised

1-Year Forecast

99.56
Limited downside

Relative Strength

85 / 100
Strongly outperforming

Business Description

Halozyme Therapeutics is a biopharmaceutical company based in San Diego, California, that develops a proprietary enzyme technology enabling drugs to be delivered by injection just beneath the skin rather than through a vein. This approach, built around its patented rHuPH20 enzyme, is licensed to many of the world's leading pharmaceutical companies and supports a wide range of treatments for conditions including cancer, multiple sclerosis, and autoimmune diseases. Founded in 1998, the company operates across the United States and several international markets, generating revenue primarily through its partnerships and licensing agreements rather than direct drug sales.

Key Fundamentals

EPS3.41
P/E31.86
ROE166
RPS13.62
ROIC34.41
ROA17.16
Interest Cover45.84
EBITDA, mln718
EV / EBITDA19.57
EV / EBIT23.29
Revenue, mln1,664
EV / Revenue8.45

Financial Strength

Altman Z-Score4.09
Piotroski F-Score 5 / 9
Beneish M-Score-1.9
Price to Lynch Fair Value1.16
1-Year Target Price99.56
Shiller PE Ratio75.92
Short Ratio7.87
Short % of Float16.19

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 5.48% 87 / 100   
1 Month 32.6% 94 / 100   
2 Months 61.86% 97 / 100   
6 Months 53.79% 93 / 100   
1 Year 51.71% 86 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us